Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.
Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J, Kurlander R, Ghetie V, Read EJ, Solomon SR, Vitetta ES, Barrett AJ. Mielke S, et al. Among authors: vitetta es. Blood. 2007 Sep 1;110(5):1689-97. doi: 10.1182/blood-2007-03-079160. Epub 2007 May 3. Blood. 2007. PMID: 17478639 Free PMC article. Clinical Trial.
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.
Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman SF, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES, Barrett AJ. Solomon SR, et al. Among authors: vitetta es. Blood. 2005 Aug 1;106(3):1123-9. doi: 10.1182/blood-2005-01-0393. Epub 2005 Apr 7. Blood. 2005. PMID: 15817673 Free PMC article. Clinical Trial.
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.
Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. Amrolia PJ, et al. Blood. 2006 Sep 15;108(6):1797-808. doi: 10.1182/blood-2006-02-001909. Epub 2006 Jun 1. Blood. 2006. PMID: 16741253 Free PMC article. Clinical Trial.
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.
Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J, Hansen JA, Nash RA, Petersdorf EW, Storb R, Ghetie V, Schindler J, Vitetta ES. Martin PJ, et al. Among authors: vitetta es. Biol Blood Marrow Transplant. 2004 Aug;10(8):552-60. doi: 10.1016/j.bbmt.2004.04.002. Biol Blood Marrow Transplant. 2004. PMID: 15282533 Free article. Clinical Trial.
Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.
Solomon SR, Tran T, Carter CS, Donnelly S, Hensel N, Schindler J, Bahceci E, Ghetie V, Michálek J, Mavroudis D, Read EJ, Vitetta ES, Barrett AJ. Solomon SR, et al. Among authors: vitetta es. Cytotherapy. 2002;4(5):395-406. doi: 10.1080/146532402320775982. Cytotherapy. 2002. PMID: 12473206
Immunology. Considering therapeutic antibodies.
Vitetta ES, Ghetie VF. Vitetta ES, et al. Science. 2006 Jul 21;313(5785):308-9. doi: 10.1126/science.1130482. Science. 2006. PMID: 16857927 No abstract available.
429 results